Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have.

21 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Ferring launches new interactive website Guts4life for people with IBD

Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn's disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD).

19 May 2014

Study finds increased risk of hospitalization for heart failure in IBD patients

Heart failure hospitalisation more than doubles during inflammatory bowel disease (IBD) flares, according to a study of more than 5 million Danish people. The research was presented today at the Heart Failure Congress 2014, held 17-20 May, in Athens, Greece.

19 May 2014

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will be recognized and awarded with the honorary degree, Doctor of Science Honoris Causa, from his alma mater, the University of Missouri - St. Louis, at a commencement ceremony this Saturday, May 17, 2014.

15 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Ajinomoto announces Phase 2a results of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients

Ajinomoto Pharmaceuticals Co., Ltd. (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) announced on May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist, AJM300, in patients with ulcerative colitis were presented in the Joint Presidential Plenary Session at Digestive Disease Week (DDW) 2014 held May 3 - 6 in Chicago, IL, USA.

13 May 2014

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers.

9 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.

2 May 2014

Scientists receive $2.3M grant to develop new technology to diagnose cancer, rheumatoid arthritis and colitis

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $2.3 million grant from the National Institute of General Medical Sciences of the National Institutes of Health to develop new technology to diagnose cancer, rheumatoid arthritis and colitis.

2 May 2014

Mango consumption on ulcerative colitis and bone parameters in animal models: Studies

Three new mango-related studies were presented this week at the 2014 Federation of American Societies for Experimental Biology (FASEB) in San Diego, revealing initial findings on the effects of mango consumption on ulcerative colitis and bone parameters in animal models.

1 May 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure.

23 Apr 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

26 Mar 2014

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

6 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Cell Science Systems launches new blood test profile for GI disorders

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Ferring launches new interactive website Guts4life for people with IBD

Study finds increased risk of hospitalization for heart failure in IBD patients

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Ajinomoto announces Phase 2a results of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Scientists receive $2.3M grant to develop new technology to diagnose cancer, rheumatoid arthritis and colitis

Mango consumption on ulcerative colitis and bone parameters in animal models: Studies

Adhesion molecule offers promising therapeutic target for preventing colitis

Studies identify 2 genes highly associated with IBD

Actavis gets favorable ruling in patent suit against generic Lialda

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

Important facts about colorectal cancer

Scientists map key elements of immune overreaction triggered by influenza virus infection

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in